Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2004 1
2007 1
2009 1
2010 1
2012 1
2013 5
2014 5
2015 5
2016 12
2017 19
2018 42
2019 34
2020 50
2021 48
2022 67
2023 60
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for jiaxing lung
Your search for Jiating Long retrieved no results
Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y. Miao D, et al. Cancer Commun (Lond). 2024 Jan;44(1):23-46. doi: 10.1002/cac2.12505. Epub 2023 Nov 20. Cancer Commun (Lond). 2024. PMID: 37985191 Free PMC article. Review.
Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one-third of affected patients have locally advanced NSCLC (LA- …
Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCL …
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Tang X, Yu J, Maher E, Feng H, Yao S, Keegan P, Wang J. Wang Z, et al. J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7. J Clin Oncol. 2023. PMID: 36206498 Free PMC article. Clinical Trial.
PURPOSE: The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients (N = 465) with treatment-naive, advanced NSCLC withou …
PURPOSE: The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment …
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, Song Z, Li Z, Yu J, Zhong W, Wang Z, Liu J, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Lin G, Huang L, Yuan J, Jiang Z, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhou J, Zhu Z, Pan W, Dong X, Pang F, Wang K, Yao C, Lin G, Li S, Yang Z, Luo J, Jia H, Nie X, Wang L, Zhu Y, Hu X, Xie Y, Lin X, Cai J, Xia Y, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Kang J, Zhang J, Zhang C, Gao W, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Yu G, Shi L, Xia Y, Gao F, Zhang X, Xu T, Zhou W, Wang H, Liu Z, Yang N, Wu L, Wang Q, Wang G, Hong Z, Wang J, Fang M, Fang Y, Zhang Y, Song Y, Ma S, Fang W, Lu Y. Zhang S, et al. Thorac Cancer. 2023 Jan;14(1):91-104. doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28. Thorac Cancer. 2023. PMID: 36444143 Free PMC article.
Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC …
Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major …
Efficient intervention for pulmonary fibrosis via mitochondrial transfer promoted by mitochondrial biogenesis.
Huang T, Lin R, Su Y, Sun H, Zheng X, Zhang J, Lu X, Zhao B, Jiang X, Huang L, Li N, Shi J, Fan X, Xu D, Zhang T, Gao J. Huang T, et al. Nat Commun. 2023 Sep 18;14(1):5781. doi: 10.1038/s41467-023-41529-7. Nat Commun. 2023. PMID: 37723135 Free PMC article.
Herein, we report the generation of high-powered mesenchymal stem cells with promoted mitochondrial biogenesis and facilitated mitochondrial transfer to injured lung cells by the sequential treatment of pioglitazone and iron oxide nanoparticles. ...We perform studies in mo …
Herein, we report the generation of high-powered mesenchymal stem cells with promoted mitochondrial biogenesis and facilitated mitochondrial …
Epithelium- and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response.
Feng Z, Zhou J, Liu Y, Xia R, Li Q, Yan L, Chen Q, Chen X, Jiang Y, Chao G, Wang M, Zhou G, Zhang Y, Wang Y, Xia H. Feng Z, et al. Cell Death Differ. 2021 Jul;28(7):2238-2256. doi: 10.1038/s41418-021-00750-x. Epub 2021 Mar 22. Cell Death Differ. 2021. PMID: 33753901 Free PMC article.
Flt3(+) AMs and Tie2(+) AMs had different immune properties, and RGS1 expression in the cells was targeted by exosomes (EXOs) containing miR-223 and miR-27b-3p that were derived from vascular endothelial cells (EnCs) and type II alveolar epithelial cells (EpCs-II), respectively. …
Flt3(+) AMs and Tie2(+) AMs had different immune properties, and RGS1 expression in the cells was targeted by exosomes (EXOs) containing miR …
Exosomal STIMATE derived from type II alveolar epithelial cells controls metabolic reprogramming of tissue-resident alveolar macrophages.
Feng Z, Jing Z, Li Q, Chu L, Jiang Y, Zhang X, Yan L, Liu Y, Jiang J, Xu P, Chen Q, Wang M, Yang H, Zhou G, Jiang X, Chen X, Xia H. Feng Z, et al. Theranostics. 2023 Jan 22;13(3):991-1009. doi: 10.7150/thno.82552. eCollection 2023. Theranostics. 2023. PMID: 36793853 Free PMC article.
Background: Complete abolition of alveolar epithelial cells (AECs) is characteristic of end-stage lung disease. Transplantation therapy of type II AECs (AEC-IIs) or AEC-IIs-derived exosomes (ADEs) have been proposed as a means of repairing injury and preventing fibrosis. . …
Background: Complete abolition of alveolar epithelial cells (AECs) is characteristic of end-stage lung disease. Transplantation thera …
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
Xu C, Si L, Wang W, Li Z, Song Z, Wang Q, Liu A, Yu J, Fang W, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Pu X, Lin R, Liu W, Rao C, Lv D, Yu Z, Lei L, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Hu X, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Ge R, Dai E, Han Y, Pan W, Luo J, Jia H, Dong X, Pang F, Wang K, Wang L, Zhu Y, Xie Y, Lin X, Cai J, Wei J, Lan F, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Wei Q, Kang J, Zhang J, Zhang C, Yu G, Ou J, Shi L, Li Z, Liu Z, Liu J, Yang N, Wu L, Wang H, Jin G, Yang L, Wang G, Fang M, Fang Y, Li Y, Wang X, Zhang Y, Ma S, Wang B, Zhang X, Song Y, Lu Y. Xu C, et al. Thorac Cancer. 2022 Nov;13(21):3084-3097. doi: 10.1111/1759-7714.14644. Epub 2022 Sep 20. Thorac Cancer. 2022. PMID: 36127731 Free PMC article.
Breast metastatic tumors in lung can be substituted by lung-derived malignant cells transformed by alternative splicing H19 lncRNA.
Xu JB, Cao J, Xia J, Zhu Y, He Y, Cao MG, Fang BM, Thiery JP, Zhou W. Xu JB, et al. Breast Cancer Res. 2023 May 30;25(1):59. doi: 10.1186/s13058-023-01662-z. Breast Cancer Res. 2023. PMID: 37254190 Free PMC article.
Here, we modified the classical MMTV-PyMT breast carcinoma model to trace the fate of mammary-derived carcinoma cells. We show that within the lung, when the metastatic breast carcinoma cells are conditionally depleted, transformed lung epithelial cells generate new …
Here, we modified the classical MMTV-PyMT breast carcinoma model to trace the fate of mammary-derived carcinoma cells. We show that within t …
Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.
Sun D, Wu W, Wang L, Qu J, Han Q, Wang H, Song S, Liu N, Wang Y, Hou H. Sun D, et al. J Transl Med. 2023 Feb 25;21(1):150. doi: 10.1186/s12967-023-03999-7. J Transl Med. 2023. PMID: 36829199 Free PMC article. Review.
METHODS: The data from 30876 lung cancer patients from the LAVA database and 7966 patients from cBioPortal database were screened. ...CONCLUSION: MET fusions are rare, and half of the fusion types were intragenic fusions. Lung cancer patients harboring primary or ac …
METHODS: The data from 30876 lung cancer patients from the LAVA database and 7966 patients from cBioPortal database were screened. .. …
The Cellular and Molecular Mechanism of Radiation-Induced Lung Injury.
Huang Y, Zhang W, Yu F, Gao F. Huang Y, et al. Med Sci Monit. 2017 Jul 15;23:3446-3450. doi: 10.12659/msm.902353. Med Sci Monit. 2017. PMID: 28710886 Free PMC article. Review.
The lung is one of several moderately radiosensitive organs. Radiation-induced lung injury (RILI), including acute radiation pneumonitis and chronic radiation-induced pulmonary fibrosis, occurs most often in radiotherapy of lung cancer, esophageal cancer, and …
The lung is one of several moderately radiosensitive organs. Radiation-induced lung injury (RILI), including acute radiation p …
341 results